[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP066349A - Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales - Google Patents

Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales

Info

Publication number
ECSP066349A
ECSP066349A EC2006006349A ECSP066349A ECSP066349A EC SP066349 A ECSP066349 A EC SP066349A EC 2006006349 A EC2006006349 A EC 2006006349A EC SP066349 A ECSP066349 A EC SP066349A EC SP066349 A ECSP066349 A EC SP066349A
Authority
EC
Ecuador
Prior art keywords
novedosos
antitumor agents
transfer inhibitors
protein transfer
compounds
Prior art date
Application number
EC2006006349A
Other languages
English (en)
Spanish (es)
Inventor
Viyyoor M Girijavallabhn
F George Njoroge
Alan B Cooper
Dinanath F Rane
Ronald J Doll
James J-S Wang
Jagdish A Desai
Hugh Y Zhu
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34138747&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066349(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP066349A publication Critical patent/ECSP066349A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EC2006006349A 2003-08-07 2006-02-06 Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales ECSP066349A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49326903P 2003-08-07 2003-08-07
US49850903P 2003-08-28 2003-08-28

Publications (1)

Publication Number Publication Date
ECSP066349A true ECSP066349A (es) 2006-08-30

Family

ID=34138747

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006349A ECSP066349A (es) 2003-08-07 2006-02-06 Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales

Country Status (19)

Country Link
US (1) US7557107B2 (fr)
EP (1) EP1660477B1 (fr)
JP (1) JP2007501791A (fr)
KR (1) KR20060057599A (fr)
AR (1) AR045447A1 (fr)
AT (1) ATE417041T1 (fr)
AU (1) AU2004263493A1 (fr)
BR (1) BRPI0413384A (fr)
CA (1) CA2535210A1 (fr)
DE (1) DE602004018332D1 (fr)
EC (1) ECSP066349A (fr)
ES (1) ES2317047T3 (fr)
HK (1) HK1087122A1 (fr)
IL (1) IL173514A0 (fr)
MX (1) MXPA06001483A (fr)
PE (1) PE20050336A1 (fr)
RU (1) RU2006106768A (fr)
TW (1) TW200510384A (fr)
WO (1) WO2005014577A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
CA2484000A1 (fr) * 2002-05-24 2003-12-04 Schering Corporation Anticorps anti-igfr humain neutralisant
TW200412956A (en) * 2002-09-30 2004-08-01 Schering Corp Methods for treating disorders of calcium homeostasis
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
MY138124A (en) * 2004-12-21 2009-04-30 Schering Corp Novel farnesyl protein transferase inhibitors as antitumor agents
MX2007012778A (es) * 2005-04-12 2008-01-11 Elan Pharma Int Ltd Formulaciones de derivados de quinazolina nanoparticuladas.
WO2006113483A2 (fr) * 2005-04-15 2006-10-26 Schering Corporation Methodes et compositions pour le traitement ou la prevention du cancer
CN101400656A (zh) * 2006-01-19 2009-04-01 先灵公司 作为法呢基蛋白转移酶抑制剂的哌嗪衍生物
EP1854465A1 (fr) * 2006-05-12 2007-11-14 Alexander Tobias Teichmann Utilisation du 4,17 béta-dihydroxyandrost-4-ene-3-one pour traiter les cancers
AU2007306139B2 (en) * 2006-10-11 2014-02-27 Fusion Antibodies Limited Combination therapy
CA2703203C (fr) 2007-10-22 2015-12-15 Schering Corporation Derives heterocycliques bicycliques et leurs procedes d'utilisation
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
CN112755193A (zh) 2012-06-26 2021-05-07 德玛医药 使用卫康醇或其衍生物治疗抗酪氨酸激酶抑制剂的恶性肿瘤的方法
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
CN1326847C (zh) 1995-12-22 2007-07-18 先灵公司 三环酰胺类用于抑制g－蛋白功能及治疗增生疾病
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
JP2003525239A (ja) 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ タキサン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US20030229099A1 (en) * 2000-08-30 2003-12-11 Zhu Hugh Y. Novel farnesyl protein transferase inhibitors as antitumor agents
AR033680A1 (es) 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
MXPA04005425A (es) * 2001-12-03 2004-10-11 Schering Corp Uso de inhibidores de farnesil proteina transferasa y por lo menos dos agentes antineoplasicos en el tratamiento de cancer.
TW200412956A (en) * 2002-09-30 2004-08-01 Schering Corp Methods for treating disorders of calcium homeostasis
MY138124A (en) 2004-12-21 2009-04-30 Schering Corp Novel farnesyl protein transferase inhibitors as antitumor agents

Also Published As

Publication number Publication date
BRPI0413384A (pt) 2006-10-17
EP1660477B1 (fr) 2008-12-10
IL173514A0 (en) 2006-07-05
PE20050336A1 (es) 2005-05-30
EP1660477A1 (fr) 2006-05-31
ES2317047T3 (es) 2009-04-16
ATE417041T1 (de) 2008-12-15
KR20060057599A (ko) 2006-05-26
AU2004263493A1 (en) 2005-02-17
DE602004018332D1 (de) 2009-01-22
WO2005014577A1 (fr) 2005-02-17
US7557107B2 (en) 2009-07-07
MXPA06001483A (es) 2006-05-15
WO2005014577A9 (fr) 2006-03-23
TW200510384A (en) 2005-03-16
HK1087122A1 (en) 2006-10-06
US20050059672A1 (en) 2005-03-17
CA2535210A1 (fr) 2005-02-17
AR045447A1 (es) 2005-10-26
RU2006106768A (ru) 2007-09-20
JP2007501791A (ja) 2007-02-01

Similar Documents

Publication Publication Date Title
ECSP066349A (es) Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
ECSP066643A (es) PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
ECSP056246A (es) DERIVADOS DE PIRROLO [3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
UY27882A1 (es) Compuestos quimicos
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
PA8547701A1 (es) Nucleosidos 4 substituidos.
SV2002000478A (es) Derivados de tiofeno utiles como anticancerosos ref. pc10795aagl/bb
UY28691A1 (es) Derivados de difenilazetidona
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
BRPI0418031A (pt) inibidores de quinase fosfonato-substituìdos
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
UY28695A1 (es) Derivados de difenilazetidona
AR063097A1 (es) Pirazolopirimidinas[1,5-a] inhibidoras de quinasas dependientes de ciclina(cdk), composiciones farmaceuticas que las contienen y usos en el tratamiento de enfermedades proliferativas
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
HN2003000272A (es) Formulaciones que comprenden un compuesto de indolinona
BR0308071A (pt) Inibidores da protéina farnesil transferase como agentes antitumores
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos